drugset

drugset / Trial / NCT03090568

Bioavailability Study of BIA 5-453

NCT03090568 ↗

Phase 1 Completed 12 enrolled Bial - Portela C S.A.

RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study was to compare the bioavailability and tolerability of BIA 5-453 under fasted and fed conditions.

Timeline

Start: 2008-07-15
Primary completion: 2008-08-14
Completion: 2008-08-14

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	BIA 5-453	Unknown	200 mg	Oral

Indications